View Clinical Trial (Medical Research Study)

Long-Term Olanzapine Treatment in Children With Autism - NCT00183404-19124(Clinical Trial 129316)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Philadelphia
State:  
PA
Zip Code: 19124
Conditions: Autism
Purpose: This study will determine the short- and long-term safety and effectiveness of the drug olanzapine (Zyprexa®) for reducing symptoms of autism in children.
Study summary: Autism is a serious childhood disorder that can significantly impair functioning and development. Educational and psychosocial programs are standard treatments for autistic children, but drug therapy is often needed as well. Haloperidol is the drug most commonly prescribed for symptoms of autism. However, long-term administration of haloperidol has been associated with adverse effects such as blurred vision, constipation, and nausea. The investigation of alternative drug treatments is necessary. This study will determine whether the antipsychotic drug olanzapine may be a safe and effective alternative to haloperidol for treating symptoms of autism in children. This study will last 36 weeks and will comprise 2 phases. In Phase I, participants will be randomly assigned to receive either olanzapine or placebo for 12 weeks. Participants who do not respond to treatment will complete their participation in the study. Participants who respond to their assigned Phase I treatment will continue onto Phase II. All Phase II participants will receive olanzapine daily for 6 months. Self-report scales and checklists will be used to assess participants after each phase; these measures will be completed by participants and their parents.
Criteria: Inclusion Criteria: - Diagnosis of autism - Parent or guardian willing to provide informed consent Exclusion Criteria: - Uncontrolled seizure disorder - Medical illness other than autism affecting the whole body - Obesity - History of psychosis - Impairment of voluntary movement - History of olanzapine treatment
Study is available at: Drexel University College of Medicine at Friends Hospital
Philadelphia, PA 19124
United States

Primary Contact:
Richard P. Malone, MD
Email: rmalone@drexelmed.edu
Phone: 215-831-4058

Secondary Contact:
Richard P. Malone, MD
Email: rmalone@drexelmed.edu
Phone: 215-831-4058
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 21, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.